background
simpl
safe
strategi
prevent
viral
respiratori
tract
infect
rti
need
object
hypothes
earli
prebiot
probiot
supplement
would
reduc
risk
virusassoci
rti
first
year
life
cohort
preterm
infant
method
random
doubleblind
placebocontrol
trial
clinicaltrialsgov
preterm
infant
gestat
age
week
birth
weight
g
treat
turku
univers
hospit
turku
finland
alloc
receiv
oral
prebiot
galactooligosaccharid
polydextros
mixtur
probiot
lactobacillu
rhamnosu
gg
atcc
placebo
microcrystallin
cellulos
day
life
primari
outcom
incid
clinic
defin
virusassoci
rti
episod
confirm
nasal
swab
use
nucleic
acid
test
secondari
outcom
sever
durat
rti
result
significantli
lower
incid
rti
detect
infant
receiv
prebiot
rate
ratio
rr
ci
p
probiot
rr
ci
p
compar
receiv
placebo
also
incid
rhinovirusinduc
episod
compris
rti
episod
found
significantli
lower
prebiot
rr
ci
p
probiot
rr
ci
p
group
compar
placebo
group
differ
emerg
among
studi
group
rhinoviru
rna
load
infect
durat
rhinoviru
rna
shed
durat
sever
rhinoviru
infect
occurr
rhinoviru
rna
asymptomat
infant
conclus
gut
microbiota
modif
specif
prebiot
probiot
might
offer
novel
costeffect
mean
reduc
risk
rhinoviru
infect
j
allergi
clin
immunol
prebiot
probiot
modul
gut
microbiota
interact
innat
adapt
immun
associ
earli
contact
microb
subsequ
develop
infecti
diseas
prompt
interest
modul
earli
hostmicrob
interact
number
sever
respiratori
tract
infect
rti
common
caus
pathogenrel
infant
morbid
develop
develop
countri
shown
studi
reduc
probiot
prebiot
intervent
although
effect
well
establish
prematur
infant
lack
initi
matur
signal
immatur
immun
system
stepwis
composit
develop
gut
microbiota
disturb
due
delay
introduct
enter
feed
lack
fresh
breast
milk
frequent
antibiot
use
neonat
intens
care
unit
environ
consequ
infant
heighten
suscept
infect
identifi
simpl
costeffect
safe
strategi
prevent
rti
essenti
mind
hypothes
earli
modif
gut
microbi
immunolog
environ
specif
prebiot
probiot
would
reduc
risk
viral
rti
preterm
infant
first
year
life
random
doubleblind
placebocontrol
studi
conduct
preterm
infant
treat
turku
univers
hospit
turku
finland
june
may
http
wwwclinicaltrialsgovctguishow
infant
recruit
first
third
day
life
inclus
criteria
follow
gestat
age
week
birth
weight
greater
g
absenc
congenit
defect
prevent
enter
nutrit
standard
care
unit
give
either
matern
pasteur
donat
breast
milk
preterm
infant
studi
compli
declar
helsinki
revis
written
inform
consent
obtain
parent
infant
studi
protocol
approv
ethic
committe
hospit
district
southwest
finland
major
challeng
trial
recruit
patient
finland
use
commerci
avail
probiot
abbrevi
use
rr
rate
ratio
rsv
respiratori
syncyti
viru
rti
respiratori
tract
infect
product
even
among
newborn
highli
widespread
parent
recruit
want
particip
studi
want
give
infant
probiot
baselin
subject
randomli
assign
one
studi
group
fig
accord
computergener
block
random
infant
prebiot
probiot
placebo
group
random
list
gener
statistician
involv
recruit
studi
subject
famili
studi
hospit
personnel
blind
random
code
seal
envelop
contain
subject
number
correspond
number
prebiot
probiot
placebo
contain
code
accord
random
list
member
research
group
involv
conduct
report
studi
research
nurs
research
ensur
prepar
correspond
number
given
subject
trial
data
collect
print
case
record
form
member
research
group
perform
data
entri
data
kept
confidenti
random
receiv
prebiot
mixtur
polydextros
danisco
sweeten
surrey
unit
kingdom
galactooligosaccharid
friesland
food
domo
zwoll
netherland
ratio
mgday
day
mgday
day
probiot
lactobacillu
rhamnosu
gg
atcc
mead
johnson
co
evansvil
ind
dose
colonyform
unitsday
day
colonyform
unitsday
day
placebo
microcrystallin
cellulos
dextros
anhydr
chr
hansen
denmark
took
place
doubleblind
manner
fig
studi
product
prepar
turku
univers
hospit
pharmaci
prebiot
probiot
placebo
prepar
look
smell
tast
ident
contain
store
viabil
probiot
confirm
mean
regular
analysi
blind
laboratori
function
food
forum
turku
univers
complianc
consumpt
studi
contain
assess
mean
interview
parent
taught
studi
nurs
mix
product
immedi
administr
infant
approxim
ml
breast
milk
formula
administ
spoon
bottl
enrol
day
followup
visit
schedul
age
month
studi
nurs
addit
schedul
studi
visit
studi
clinic
addit
telephon
call
parent
infant
age
month
weight
height
head
circumfer
measur
growth
chart
sketch
visit
studi
visit
parent
report
infant
behavior
pattern
includ
sleep
pattern
fuss
cri
irrit
feed
vomit
stool
consist
normal
loos
firm
hard
atyp
frequenc
daili
infect
diseas
medic
use
addit
advers
event
queri
parent
visit
data
publish
detail
elsewher
furthermor
parent
kept
structur
diari
child
physician
offic
visit
pharmacolog
treatment
followup
period
inform
collect
diari
well
parent
studi
visit
infant
clinic
examin
physician
age
month
deem
necessari
sign
symptom
acut
infect
primari
outcom
present
studi
incid
defin
viral
rti
confirm
nasal
swab
use
nucleic
acid
test
secondari
outcom
effect
intervent
sever
durat
defin
viral
rti
symptomat
rti
episod
defin
child
least
follow
symptom
fever
temperatur
rhiniti
cough
infecti
diseas
symptom
document
parent
use
structur
question
parent
daili
diari
addit
follow
symptom
record
nasal
congest
excess
cri
restlessnessirrit
poor
appetit
vomit
throw
partial
digest
food
drink
diarrhea
loos
stool
daili
occurr
durat
fever
temperatur
greater
consid
signific
sever
symptom
individu
fever
rhiniti
cough
nasal
congest
excess
cryingrestlessnessirrit
poor
appetit
vomit
throw
partial
digest
food
drink
diarrhea
loos
stool
daili
score
parent
daili
mild
moder
sever
mean
symptom
score
regard
sever
score
episod
durat
symptom
measur
day
symptom
rti
nasal
swab
flock
nylon
nasal
swab
copan
brescia
itali
depth
cm
taken
home
day
ill
detect
respiratori
tract
virus
use
nucleic
acid
test
addit
nasal
swab
taken
studi
visit
age
month
infant
asymptomat
infant
rti
symptom
time
studi
visit
asymptomat
sampl
taken
week
symptom
disappear
subgroup
children
n
swab
collect
day
verifi
subclin
rhinoviru
infect
research
nurs
taught
parent
techniqu
obtain
nasal
swab
sampl
swab
mail
laboratori
dri
steril
tube
store
analysi
swab
specimen
suspend
ml
pb
total
nucleic
acid
extract
ml
suspens
use
magna
pure
extractor
roch
mannheim
germani
elut
volum
ml
human
bocaviru
dna
detect
use
quantit
pcr
ml
extract
revers
transcript
perform
reaction
use
ml
extract
random
hexam
primer
revertaid
h
cdna
synthesi
reagent
fermenta
st
leonrot
germani
rhinoviru
enterovirus
respiratori
syncyti
viru
rsv
rna
detect
ml
cdna
use
quantit
pcr
addit
adenoviru
coronavirus
influenza
b
virus
human
metapneumoviru
parainfluenza
viru
type
rsv
group
b
rhinoviru
detect
use
seeplex
multiplex
pcr
assay
seegen
seoul
korea
altogeth
pcr
test
carri
overal
aim
studi
balanc
gut
microbiota
composit
preterm
infant
prebiot
probiot
supplement
consequ
improv
infant
wellb
reduc
diseas
risk
studi
sever
outcom
variabl
present
articl
describ
effect
prebiot
probiot
intervent
incid
rti
data
analyz
base
complet
case
analysi
categor
variabl
analyz
use
x
test
fisher
exact
test
dichotom
variabl
univari
associ
continu
variabl
analyz
use
anova
kruskallw
test
neg
binomi
regress
use
compar
incid
rti
rhinoviru
infect
among
studi
group
result
given
rate
ratio
rr
ci
addit
associ
studi
use
antenat
steroid
deliveri
method
sex
postnat
antibiot
older
sibl
home
covari
child
could
multipl
viral
episod
follow
analys
made
repeatedmeasur
method
viral
copi
number
compar
studi
group
use
nonparametr
repeatedmeasur
analysi
comparison
group
made
use
gener
estim
equat
durat
intens
clinic
symptom
associ
area
curv
viral
copi
number
durat
sever
symptom
studi
use
mix
model
mean
gestat
age
infant
week
rang
week
mean
birth
weight
g
rang
g
studi
period
complet
infant
fig
twentyf
infant
discontinu
studi
drop
age
month
rti
report
age
point
baselin
clinic
characterist
infant
pregnanc
mother
infant
tabl
found
repres
origin
popul
recruit
total
particip
infant
age
month
age
month
consum
capsul
regularli
daili
without
signific
differ
among
studi
group
p
respect
studi
popul
advers
effect
record
advers
event
reason
noncompli
case
infant
sever
infect
followup
period
total
number
clinic
rti
episod
whole
studi
popul
followup
period
number
rti
episod
prebiot
group
probiot
group
placebo
group
case
put
caus
viru
detect
rhinoviru
common
viru
found
episod
two
virus
detect
case
case
case
tabl
ii
rate
find
multipl
virus
prebiot
group
probiot
group
placebo
group
signific
differ
detect
among
group
incid
rti
mean
sd
prebiot
group
sd
probiot
group
sd
placebo
group
p
tabl
iii
differ
seen
throughout
studi
period
take
rhinoviru
sole
sourc
infect
incid
significantli
lower
prebiot
group
rr
ci
p
probiot
group
rr
ci
p
compar
placebo
group
wherea
differ
intervent
group
reach
statist
signific
rr
ci
p
sensit
analysi
reanalyz
main
result
incid
rti
rhinoviru
infect
assum
miss
subject
either
good
outcom
percentil
bad
outcom
percentil
assum
miss
subject
good
outcom
percentil
result
remain
alik
significantli
lower
incid
rti
detect
infant
receiv
prebiot
rr
ci
p
probiot
rr
ci
p
compar
receiv
placebo
also
incid
rhinovirusinduc
episod
found
significantli
lower
prebiot
rr
ci
p
probiot
rr
ci
p
group
compar
placebo
group
assum
miss
subject
would
bad
outcom
percentil
result
follow
significantli
similarli
incid
rti
rhinoviru
infect
adjust
use
antenat
corticosteroid
postnat
antibiot
mode
deliveri
sex
presenc
older
sibl
home
signific
differ
emerg
among
studi
group
p
five
case
human
bocaviru
infect
infant
detect
placebo
group
concomit
rhinoviru
mean
durat
symptom
rhinoviru
episod
se
day
prebiot
group
se
day
probiot
group
se
day
placebo
group
p
signific
differ
detect
among
group
combin
sever
score
clinic
symptom
rhinoviru
episod
median
median
score
prebiot
group
probiot
group
placebo
group
p
symptomat
rhinoviru
episod
day
median
copi
number
rhinoviru
rna
interquartil
rang
log
copiessampl
prebiot
group
interquartil
rang
log
copiessampl
probiot
group
interquartil
rang
log
copiessampl
placebo
group
p
rhinoviru
rna
copi
number
day
episod
present
fig
rel
rhinoviru
copi
number
correl
posit
durat
p
sever
symptom
data
shown
associ
similar
group
furthermor
time
day
need
viru
erad
symptomat
rhinoviru
episod
differ
among
group
p
median
erad
time
day
prebiot
probiot
group
greater
day
placebo
group
rhinoviru
common
viru
detect
asymptomat
infant
virusposit
find
tabl
iv
case
virus
case
virus
found
concomitantli
rate
find
multipl
virus
asymptomat
infant
prebiot
group
probiot
group
placebo
group
signific
differ
found
among
studi
group
occurr
rhinoviru
rna
asymptomat
infant
median
copi
number
rhinoviru
rna
nasal
swab
interquartil
rang
log
copiessampl
whole
popul
signific
differ
among
studi
group
p
fig
copi
number
rhinoviru
rna
nasal
swab
symptomat
infant
day
significantli
higher
asymptomat
subject
p
fig
durat
rhinoviru
rna
shed
asymptomat
infant
n
present
fig
rna
neg
day
differ
symptomat
infant
signific
respect
p
studi
signific
reduct
incid
rti
especi
rhinoviru
infect
first
year
life
preterm
popul
achiev
specif
prebiot
probiot
name
galactooligosaccharid
polydextros
lactobacillu
rhamnosu
gg
result
support
previous
publish
random
doubleblind
prebiot
andor
probiot
trial
conduct
healthi
term
infant
first
year
life
incid
clinic
rti
repres
outcom
tabl
v
extend
object
character
viral
caus
contrast
earlier
studi
studi
conduct
prematur
infant
supplement
commenc
within
first
week
life
might
increas
protect
efficaci
rti
moreov
effect
exert
prebiot
tend
outweigh
probiot
one
put
explan
find
might
lie
preexist
bifidobacteriadomin
gut
microbiota
breastf
preterm
popul
strengthen
effect
prebiot
select
stimul
growth
benefici
intestin
microorgan
preterm
popul
protect
effect
prebiot
probiot
achiev
rti
rhinoviru
infect
shown
extend
throughout
followup
period
immunomodulatori
effect
accomplish
time
median
rang
rhinoviru
load
log
copi
per
sampl
obtain
respiratori
symptom
present
day
episod
asymptomat
infant
studi
group
signific
differ
detect
among
studi
group
time
point
p
day
p
day
p
day
p
day
p
asymptomat
infant
differ
symptomat
infant
day
asymptomat
infant
signific
p
j
allergi
clin
immunol
volum
number
child
immunolog
phenotyp
consolid
thu
confer
clinic
benefit
beyond
intervent
period
previous
document
risk
reduct
eczema
age
year
perinat
probiot
intervent
observ
agreement
program
theori
wherebi
earlylif
exposur
carri
effect
later
life
extend
microbi
contact
fact
accord
previous
publish
clinic
studi
earli
colon
shown
potenti
exert
immunolog
effect
year
later
moreov
prevent
earli
rhinoviru
infect
might
great
clinic
import
earli
rhinoviru
infect
recent
recogn
major
predispos
factor
develop
asthma
rational
probiot
use
prevent
rti
base
abil
reduc
pathogen
colon
respiratori
epithelium
regul
mucos
immun
activ
inflammasom
also
system
immun
respons
health
benefit
probiot
bacteria
viral
diseas
previous
best
demonstr
gastrointestin
infect
relat
mainten
epitheli
barrier
integr
product
antimicrobi
factor
control
balanc
proinflammatori
antiinflammatori
cytokin
reinforc
product
antigenspecif
secretori
iga
importantli
probiot
shown
regul
express
gene
relat
innat
immunemedi
cytokin
respons
intestin
also
respiratori
mucosa
creat
antiinflammatori
milieu
thu
modul
benefici
respiratori
mucos
antibacteri
antivir
immun
recent
mous
model
studi
lactobacilli
induc
chang
express
interferonstimul
gene
increas
ifng
level
benefici
modul
respiratori
mucos
antivir
immun
mechan
analog
shield
effect
breastfeed
gastrointestin
infect
rti
mediat
passiv
immun
protect
iga
oligosaccharid
colon
bacteria
growth
factor
molecul
regul
microbi
recognit
rhinoviru
commonli
detect
respiratori
tract
viru
wide
rang
clinic
present
studi
rhinoviru
infect
record
year
preterm
popul
although
overal
rate
rti
low
put
explan
major
infant
firstborn
breastf
day
care
age
month
interestingli
prebiot
probiot
prevent
symptomat
infect
occurr
rhinoviru
rna
asymptomat
infant
agreement
find
jansen
et
al
rhinoviru
rna
copi
number
found
lower
asymptomat
infant
signific
correl
rhinoviru
rna
load
durat
clinic
symptom
although
prebiot
probiot
supplement
prevent
rhinoviru
infect
intervent
effect
durat
sever
symptomat
rhinoviru
infect
furthermor
neither
intervent
influenc
durat
viral
shed
new
observ
period
rhinoviru
rna
shed
significantli
shorter
among
asymptomat
infant
focus
prematur
infant
physiolog
immunodefici
immatur
innat
immun
system
studi
infant
placebo
group
least
rti
first
year
life
preterm
infant
significantli
reduc
proinflammatori
cytokin
tnfa
respons
produc
decreas
amount
antivir
ifna
mechan
involv
lie
reduc
pattern
recognit
receptor
express
hand
tend
mount
aberr
respons
antigen
challeng
overexpress
proinflammatori
cytokin
lead
overwhelm
hyperreact
state
consequ
lead
increas
suscept
viral
infect
also
well
establish
prematur
major
risk
factor
sever
rsv
infect
mani
recent
studi
shown
prematur
infant
also
sever
rhinoviru
infect
import
limit
studi
studi
preterm
infant
could
question
generaliz
result
fullterm
older
infant
furthermor
substanti
number
prematur
infant
underw
random
could
evalu
studi
period
addit
must
acknowledg
prebiot
probiot
draw
conclus
relationship
intervent
effect
prebiot
supplement
probiot
speci
possibl
hand
studi
first
report
effect
prebiot
probiot
prevent
defin
viral
rti
preterm
cohort
result
enhanc
placebocontrol
evid
note
sever
review
also
cochran
review
especi
data
infanc
studi
also
provid
novel
clinic
evid
rhinoviru
rna
shed
relat
clinic
pictur
symptomat
asymptomat
infant
furthermor
given
fact
probiot
live
microorgan
probiot
prebiot
possess
numer
immunolog
properti
uncertainti
still
prevail
regard
longterm
safeti
use
among
preterm
infant
period
child
immunolog
phenotyp
consolid
absenc
advers
effect
studi
cohort
repres
safeti
document
use
prebiot
probiot
sensit
infant
popul
worthi
note
infant
born
prematur
popul
thu
repres
million
infant
per
year
worldwid
preterm
infant
carri
heighten
risk
infecti
ailment
bacteri
viral
caus
undernourish
aggrav
suscept
rti
major
caus
mortal
morbid
worldwid
particularli
first
year
life
rhinoviru
main
pathogen
respons
socioeconom
burden
although
strict
hygien
measur
shown
reduc
viral
transmiss
thu
diminish
incid
rhinoviru
infect
definit
prevent
measur
thu
far
discov
effect
control
entiti
basi
result
gut
microbiota
modul
specif
prebiot
probiot
could
offer
costeffect
tool
fight
rti
hope
also
develop
world
conclus
demonstr
earli
manipul
microbiota
preterm
infant
dietari
mean
might
induc
longlast
effect
could
reduc
risk
viral
rti
